T1	Disorder 19 39	hematologic neoplasm
N1 	Reference T1 UMLS:C0376545	hematologic neoplasm
T2	Disorder 159 181	hematologic malignancy
N2 	Reference T2 UMLS:C0376545	hematologic malignancy
T3	Disorder 243 257	bladder cancer
N3 	Reference T3 UMLS:C0005684	bladder cancer
T4	Pharmacological_substance 274 285	doxorubicin
N1000 	Reference T4 MeSH:D004317	doxorubicin
T5	Pharmacological_substance 291 302	mitomycin C
N1001 	Reference T5 MeSH:D016685	mitomycin C
T6	Disorder 384 394	malignancy
N4 	Reference T6 UMLS:C1306459	malignancy
T7	Disorder 439 456	refractory anemia
N5 	Reference T7 UMLS:C0002893	refractory anemia
N6 	Reference T7 UMLS:C2981142	refractory anemia
T8	Disorder 500 530	acute non-lymphocytic leukemia
N7 	Reference T8 UMLS:C0023467	acute non-lymphocytic leukemia
T9	Disorder 88 105	bladder carcinoma
N8 	Reference T9 UMLS:C0699885	bladder carcinoma
T12	Pharmacological_substance 263 272	etoglucid
N1002 	Reference T12 MeSH:D005009	etoglucid
T15	Pharmacological_substance 532 557	Intravesical chemotherapy
T17	Disorder 591 611	secondary malignancy
N9 	Reference T17 UMLS:C2939419	secondary malignancy
N10 	Reference T17 UMLS:C2939419	secondary malignancy
N11 	Reference T17 UMLS:C2939419	secondary malignancy
N12 	Reference T17 UMLS:C2939419	secondary malignancy
N13 	Reference T17 UMLS:C2939419	secondary malignancy
N14 	Reference T17 UMLS:C2939419	secondary malignancy
T18	Speculation_cue 558 564	may be
T11	Pharmacological_substance 46 71	intravesical chemotherapy
T13	Pharmacological_substance 202 227	intravesical chemotherapy
